Emergent BioSolutions (EBS) Q3 2026 Earnings Call Transcript

Emergent BioSolutions reported Q3 2026 revenue of $110M, within guidance, bringing YTD revenue to $500M. Adjusted EBITDA reached $128M (25% margin), with $122M in operating cash flow. The company highlighted progress in its transformation plan, including contract modifications and international sales. CFO Rich Lindahl announced his retirement, with Frank Vargo assuming the role in 2027. The company also discussed its role in biodefense and AI partnerships for clinical development.

Original reporting
Published Nov 3, 2026, 5:28 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 3, 2026, 5:47 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Emergent BioSolutions (EBS) Q3 2026 Earnings Call Transcript — source image
Decision brief

The 30-second read

$EBSNeutralMed
01

Why it matters

The earnings were within guidance, but the CFO change introduces execution risk, while AI partnership signals future growth avenues.

02

Market read

EBS earnings and leadership transition provide actionable insight for biotech defense investors.

03

What to watch

AI partnership announcements hint at future growth beyond current earnings.

Relevance 7/10Novelty 7/10Timing: post-market today

Background

Emergent BioSolutions presented its Q3 2026 financial results and announced CFO retirement, highlighting ongoing contracts and AI collaborations.

Company-level read

Ticker impact

$EBSNeutralHigh confidence
Context

Q3 2026 earnings call disclosed $110M revenue, $128M adjusted EBITDA and CFO retirement, new guidance for 2026.

Expected impact

likely modest downside as market prices in CFO transition and flat revenue guidance

Evidence & confidence

Earnings are material and first disclosed; CFO change adds execution risk, prompting traders to watch near-term price action.

Market effects

MCM and naloxone segments may influence biotech defense and opioid‑antidote peers.

U.S. defense biotech stocks could see modest movement.

Limited to investors in biodefense and specialty pharma.

Counterpoint

CFO departure could be seen as a catalyst for a strategic reset, potentially boosting long‑term outlook.

Key entities

  • Emergent BioSolutions

    Biodefense and naloxone product developer.

  • Joseph Papa

    CEO of Emergent BioSolutions.

  • Rich Lindahl

    Outgoing CFO retiring Dec 31, 2026.

Related articles

$EBSMedAI 8/10

Emergent BioSolutions Inc (EBS) (Q3 2026) Earnings Call Highlights: Revenue Timing Weighs

Emergent BioSolutions reported Q3 2026 revenue of $110M, down from $231M in Q3 2025 due to MCM delivery timing. Adjusted EBITDA was -$5M, with adjusted gross margin at 28%. Full-year 2026 revenue guidance was updated to $600M-$645M. The company faces competitive pricing pressure in the naloxone market and expects MCM revenues to decline. CFO Richard Lindahl is retiring, and net leverage remained stable at 2.4 times.

$EBSMedAI 8/10

Emergent BioSolutions 2026: Revenue $110M, EPS ($0.64) — 10-Q Summary

Emergent BioSolutions reported Q3 2026 revenue of $110M, a 52.4% YoY decline, and a net loss of $32.7M, compared to a profit of $51.2M a year earlier. Nine-month revenue fell 16% to $500.4M, driven by lower NARCAN sales and declines in medical countermeasure products. The company reduced its workforce by 90 employees in August to cut costs.

$EBSMed

Emergent Biosolutions Q3 Earnings Call Highlights

Emergent Biosolutions reported Q3 cash of $176M, reduced gross debt by $179M YoY, and repurchased $75M in bonds. MCM revenue was $59M, with international sales contributing $72M. Naloxone market faced competition. 2026 revenue guidance updated to $600M-$645M. CFO to retire, interim replacement named. (EBS)

$EBSMed

EMERGENT BIOSOLUTIONS REPORTS THIRD QUARTER 2026 FINANCIAL RESULTS

Emergent BioSolutions Inc. (EBS) filed an SEC Form 8-K — Results of Operations and Financial Condition. EMERGENT BIOSOLUTIONS REPORTS THIRD QUARTER 2026 FINANCIAL RESULTS • Third Quarter 2026 Total Revenues of $110.0 million • Third Quarter 2026 Net Loss of $32.7 million and Net Loss Margin was (30)% • Third Quarter 2026 Adjusted Net Loss of $18.7 million • Third Quarter 2026 Gross